Table of Contents

Autoimmune diseases affect millions worldwide, with over 100 known conditions like rheumatoid arthritis, psoriasis, and ankylosing spondylitis causing debilitating pain and chronic discomfort. In the US alone, up to 50 million people have an autoimmune disease, making it the third most prevalent disease category after cancer and heart disease. Genes, infections, and environmental factors play significant roles in disease development.

Recent advancements in biologic therapies, specifically Enbrel and Humira, have been developed. However, choosing between them can be overwhelming due to differences in efficacy, side effects, and costs. This article offers a detailed comparison, analyzing key factors to assist individuals in making an informed decision about managing autoimmune diseases.

Key Differences Between Enbrel and Humira

Parameters Enbrel Humira
List price $7,401.84 $6,922.62
Active ingredient Etanercept Adalimumab
Approved indications Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Ulcerative Colitis, Crohn’s Disease, Uveitis
Drug classification TNF-alpha inhibitor TNF-alpha inhibitor
Dosage Forms Prefilled pen (Enbrel SureClick), single-dose prefilled syringe, single-dose vial, multiple-dose vial, single-dose prefilled cartridge Prefilled pen (Humira Pen), single-dose prefilled syringe, single-dose vial
Frequency of administration Once weekly or twice weekly Once weekly or once every other week
Effectiveness Less effective compared to Humira across multiple conditions Superior effectiveness over Enbrel across multiple conditions
Common side effects Injection site reactions and upper respiratory infections Injection site reactions and upper respiratory infections
Biosimilars Not available in the US until 2029 Available, including interchangeable biosimilars

Efficacy of Enbrel vs Humira

In evaluating the efficacy of Enbrel (etanercept) and Humira (adalimumab), various clinical studies and reviews provide insights into their performance across different conditions.

Enbrel vs Humira for Plaque Psoriasis

A study published in Value in Health compares the outcomes of using adalimumab and etanercept in treating moderate to severe plaque psoriasis. The researchers compared outcomes at week 12 between those treated with adalimumab and those treated with etanercept. The main outcomes measured included:

    • The proportion of patients achieving significant reductions in the Psoriasis Area and Severity Index (PASI75, PASI90, PASI100)
    • Symptom resolution (pruritus and psoriatic pain)
    • Lesion resolution
    • No skin-related quality of life impact
    • Complete disease control
    • Adverse events

PASI75 indicates a 75% improvement in the PASI score from baseline. Similarly, PASI90 indicates 90% improvement, while achieving PASI100 means the patient has achieved complete clearance of psoriasis with no signs of the disease remaining.

Here are the results of the study:

Outcome Adalimumab (%) Etanercept (%)
Proportion of patients achieving PASI75 62.3 42.6
Proportion of patients achieving PASI90 35.9 12.1
Proportion of patients achieving PASI100 13.1 4.9
Pruritus Resolution 24.7 13.0
Psoriatic Pain Resolution 27.4 8.7
DLQI = 0 (No skin-related quality of life impact) 27.7 11.7
PtGA = 0 (Complete Disease Control) 16.4 10.6
Adverse Events Similar
Head-specific Lesion Resolution Similar

Adalimumab showed significantly better outcomes compared to etanercept. However, the rates of adverse events and head-specific lesion resolution were similar between the two drugs.

Enbrel vs Humira for Ankylosing Spondylitis

A 2020 study investigated the efficacy and safety of adalimumab versus etanercept in treating patients with active ankylosing spondylitis. Based on the study results, adalimumab and etanercept are comparable in terms of efficacy and safety, although patients favored adalimumab slightly more.

Enbrel vs Humira for Psoriatic Arthritis

Currently, there is no direct head-to-head comparison study between Enbrel and Humira specifically for treating psoriatic arthritis. However, a comprehensive comparative review has assessed the efficacy of multiple TNF inhibitors, including etanercept and adalimumab, in treating psoriatic arthritis.

This review found no significant differences in efficacy among four TNF inhibitors after 24 weeks of treatment. These findings suggest that Enbrel and Humira are similarly effective in managing psoriatic arthritis.

Enbrel vs Humira for Rheumatoid Arthritis

In 2006, a systematic review evaluated the effectiveness of adalimumab, etanercept, and infliximab for treating rheumatoid arthritis in adults. Although the study did not conduct direct head-to-head trials of adalimumab versus etanercept, it made indirect comparisons based on their performance relative to methotrexate in separate trials.

The results indicated that etanercept was slightly more effective than adalimumab in reducing symptoms and slowing radiographic joint damage, particularly in methotrexate-naïve patients with both short and longer disease durations. Both drugs were effective in combination with methotrexate for improving rheumatoid arthritis symptoms. However, etanercept was better tolerated than methotrexate and, by implication, possibly better tolerated than adalimumab in similar patient populations.

Enbrel vs Humira for Juvenile Idiopathic Arthritis (JIA)

Researchers compared the efficacy of adalimumab and etanercept in young children (older than 4 years) with Juvenile Idiopathic Arthritis (JIA), focusing on their uveitis status. Uveitis, an inflammation of the middle layer of the eye, is crucial in determining the most effective and safe treatment regimen for JIA, as it impacts drug efficacy, the risk of complications, and the need for a tailored treatment approach.

Both etanercept and adalimumab effectively reduced disease symptoms and improved joint health in children under 4 years old. Adalimumab demonstrated higher efficacy in children with uveitis, whereas etanercept showed better results in those without uveitis. Long-term remission rates were similar between etanercept and adalimumab in children with uveitis, but significantly lower in children without uveitis treated with adalimumab.

Enbrel vs Humira for Hidradenitis Suppurativa

Enbrel vs Humira for Hidradenitis Suppurativa

In separate clinical trials, Enbrel and Humira were evaluated for treating hidradenitis suppurativa (HS), a chronic skin condition also known as acne inversa.

In 2016, two phase III trials showed that adalimumab (40 mg weekly) significantly improved clinical response rates of HS compared to placebo at 12 weeks. This was supported by a real-life data study in 2018, linking adalimumab to both clinical remission of HS and improved quality of life for patients. Furthermore, a recent study demonstrated that weekly administration of adalimumab not only led to better clinical responses than placebo but also significantly reduced disease severity and enhanced the quality of life for patients with moderate-to-severe HS.

In contrast, clinical trials failed to demonstrate etanercept’s efficacy. At a dose of 50 mg once a week, only 3 out of 15 patients showed significant improvement, defined as a 50% or greater improvement in their condition after 12 weeks. Although there were slight reductions in pain and quality of life scores, only 29% of patients reported moderate improvement.

Another more rigorously controlled study with 20 patients compared etanercept to a placebo. No significant differences in improvements were found between the two groups after 12 weeks of treatment, followed by an additional 12 weeks of open-label treatment.

Overall, Humira has strong evidence supporting its effectiveness in treating HS, whereas Enbrel did not show significant efficacy for this condition.

Enbrel vs Humira for Inflammatory Bowel Diseases (IBD)

Inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, impact millions globally, placing a substantial burden on both patients and healthcare systems.

A study evaluated the efficacy and safety of Humira for ulcerative colitis in 2021. The outcomes indicated that the adalimumab 160/80 regimen (160 mg at week 0, 80 mg at week 2, and 40 mg at weeks 4 and 6) was both safe and effective in inducing clinical remission in patients with moderately to severely active ulcerative colitis who had not responded to corticosteroids and/or immunosuppressants.

Similarly, the double-blind ENVISION I study reported clinically meaningful rates of remission and response in children who received adalimumab for moderate-to-severe ulcerative colitis.

Researchers have also evaluated Humira for Crohn’s disease. A 24-week study revealed that approximately two-thirds of Crohn’s disease patients with symptomatic small bowel stricture responded successfully to adalimumab. Nearly half of these patients maintained prolonged success over a median follow-up period of 3.8 years. In addition, more than half of the patients avoided surgery four years after initiating adalimumab treatment.

Unfortunately, this was not the case for Enbrel. In a randomized, double-blind, placebo-controlled trial, etanercept at a dose of 25 mg twice weekly was found to be safe but not effective for treating patients with moderate to severe Crohn’s disease. Furthermore, a 2019 study revealed that patients receiving etanercept had an increased risk of being diagnosed with Crohn’s disease or ulcerative colitis. The exact nature of this association, however, remains unclear.

Enbrel vs Humira for Uveitis

A study published in the BMJ Open Ophthalmology showed that adalimumab is effective in treating patients with vision-threatening, non-infectious uveitis. It helped preserve vision and enabled a significant reduction in corticosteroid use. In a separate study, etanercept did not demonstrate significant efficacy compared to placebo in preventing uveitis relapses in patients tapering off methotrexate.

Additionally, a number of studies report that etanercept may induce uveitis. Experts analyzed data from two extensive databases, identifying 59 uveitis cases. They discovered that 43 cases (73%) were associated with etanercept. In 2011, another study examined 152 new-onset uveitis cases. Of these cases, 84% were linked to etanercept.

Here is the summarized table for the conditions and the comparison of Enbrel and Humira:

Condition Enbrel Humira
Plaque Psoriasis Less effective More effective
Ankylosing Spondylitis Comparable Comparable, slightly favored
Psoriatic Arthritis Similar Similar
Rheumatoid Arthritis Slightly more effective Slightly less effective
Juvenile Idiopathic Arthritis (JIA) More effective in patients without uveitis More effective in patients with uveitis
Hidradenitis Suppurativa Showed limited effectiveness (only 3 out of 15 patients showed significant improvement) Effective
Ulcerative Colitis Not effective, associated with increased risk Effective
Crohn’s Disease Not effective, associated with increased risk Effective
Uveitis Not effective, associated with increased risk Effective

Humira consistently demonstrated superior effectiveness over Enbrel across multiple conditions. Additionally, Enbrel’s association with an increased risk of inflammatory bowel diseases and uveitis poses a significant concern.

Safety and Side Effects

This section provides a detailed overview of each medication’s adverse events and potential risks, including common and rare side effects. Understanding these aspects helps individuals weigh the benefits and risks, enabling them to make informed decisions about their treatment options.

Humira Side Effects

Humira comes with a range of potential side effects and risks that users should be aware of.

Common Side Effects

Patients using Humira may experience various common side effects, particularly at the injection site. These include pain, redness, rash, swelling, itching, or bruising. Additionally, some users report upper respiratory infections such as sinus infections, headaches, general rash, and nausea.

Serious Adverse Events

Humira can cause several serious side effects that require immediate medical attention. These include:

    • Serious Infections
    • Hepatitis B Reactivation
    • Allergic Reactions
    • Nervous System Issues
    • Blood Disorders
    • Heart Failure
    • Immune Reactions
    • Liver Problems
    • Psoriasis

Risk of Malignancies

Humira increases the risk of serious infections and certain cancers. Users, including children and adults, have a higher likelihood of developing lymphoma and other cancers. Reports indicate that some young individuals have developed hepatosplenic T-cell lymphoma, a rare and often fatal cancer.

Additionally, there is an increased risk of skin cancers, such as basal cell carcinoma and squamous cell carcinoma, which are generally not life-threatening if treated promptly. Patients should notify their doctor if they notice any unusual bumps or open sores that do not heal.

Enbrel Side Effects

Similarly, Enbrel is also associated with potential side effects and risks that patients need to be aware of.

Common Side Effects

Patients using Enbrel frequently report common side effects, particularly at the injection site. These include pain, redness, swelling, itching, and bruising. Additionally, users may experience upper respiratory infections such as sinus infections.

Serious Adverse Events

Enbrel may lead to a number of severe side effects that necessitate immediate medical attention. These are:

    • Serious Infections
    • Nervous System Issues
    • Blood Disorders
    • Heart Failure
    • Psoriasis
    • Allergic Reactions
    • Autoimmune Reactions

Risk of Malignancies

Enbrel, like other TNF blockers, increases the risk of serious infections and certain cancers. Children, teenagers, and adults using Enbrel have a heightened risk of developing lymphoma and other types of cancers. There have been reports of unusual cancers, some resulting in death, particularly in children and teenagers who began using TNF blockers before the age of 18. Patients with rheumatoid arthritis may have an elevated risk of developing lymphoma compared to the general population.

In summary, while Enbrel and Humira are effective for many patients, it is essential to be aware of their potential side effects and risks. Close monitoring and regular consultations with a healthcare provider can help manage and mitigate these risks.

Mechanism of Action: Humira vs. Enbrel

A close-up 3D rendering of a complex molecular structure.

Humira and Enbrel target tumor necrosis factor-alpha (TNF-alpha) to manage autoimmune diseases, but they do so through different mechanisms. TNF-alpha is a cytokine that plays a key role in systemic inflammation as part of the immune system’s response.

Humira, as a monoclonal antibody, binds directly to TNF-alpha, blocking its interaction with TNF receptors on the cell surface. Enbrel, on the other hand, is a fusion protein composed of the TNF receptor linked to the Fc portion of human immunoglobulin G1 (IgG1). This structure allows Enbrel to act as a decoy receptor for TNF-alpha capturing it before it can bind to its natural receptors on the cell surface.

This difference in mechanism can influence their efficacy, administration, and side effect profiles, though both have been validated through numerous clinical trials for their effectiveness in reducing the symptoms of inflammatory diseases.

Indications and Approvals

Humira and Enbrel are two widely used biologic medications primarily prescribed to treat various autoimmune and inflammatory conditions.

What is Humira Used For?

As the third TNF-alpha inhibitor to receive FDA approval, adalimumab followed the earlier approvals of infliximab and etanercept.

FDA-Approved Indications

The FDA first approved Humira on December 31, 2002, for the treatment of rheumatoid arthritis. Over time, the FDA has extended its approval to adalimumab for various other indications. These include:

  • Rheumatoid Arthritis (RA): Humira is approved for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adults with moderately to severely active RA. It can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
  • Juvenile Idiopathic Arthritis (JIA): It is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older. Humira can be used alone or in combination with methotrexate.
  • Psoriatic Arthritis (PsA): Humira is used to reduce signs and symptoms, inhibit the progression of structural damage, and improve physical function in adults with active psoriatic arthritis. It can be used alone or in combination with non-biologic DMARDs.
  • Ankylosing Spondylitis (AS): Approved for reducing signs and symptoms in adults with active ankylosing spondylitis.
  • Crohn’s Disease (CD): Humira is indicated for treating moderately to severely active Crohn’s disease in adults and pediatric patients aged 6 years and older.
  • Ulcerative Colitis (UC): It is approved for treating moderately to severely active ulcerative colitis in adults and pediatric patients aged 5 years and older. Its effectiveness in patients who have lost response to or were intolerant to TNF blockers has not been established.
  • Plaque Psoriasis (Ps): Humira is indicated for treating adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, especially when other systemic therapies are less appropriate.
  • Hidradenitis Suppurativa (HS): Approved for treating moderate to severe hidradenitis suppurativa in patients aged 12 years and older.
  • Uveitis: Indicated for treating non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients aged 2 years and older.

Off-Label Uses

Humira is also occasionally prescribed off-label for a range of conditions, such as:

    • Sarcoidosis
    • Pyoderma Gangrenosum
    • Behcet Disease
    • Pityriasis Rubra Pilaris
    • Lichen Panus
    • Alopecia Areata
    • Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome (SAPHO Syndrome)
    • Granulomatosis with Polyangiitis (Wegener Granulomatosis)
    • Pemphigus
    • Multicentric Reticulohistiocytosis

What is Enbrel Used For?

Enbrel received its initial approval in 1998 for the treatment of moderate-to-severe rheumatoid arthritis. In 2003, it became the first biologic approved for active ankylosing spondylitis.

FDA Approved Uses

Enbrel is indicated for several chronic inflammatory conditions, including:

  • Rheumatoid Arthritis (RA): Used to reduce signs and symptoms, achieve a major clinical response, inhibit structural damage progression, and improve physical function in patients with moderately to severely active RA, either alone or in combination with methotrexate (MTX).
  • Polyarticular Juvenile Idiopathic Arthritis (JIA): Approved for reducing signs and symptoms in patients aged 2 years and older with moderately to severely active polyarticular JIA.
  • Psoriatic Arthritis (PsA): Indicated for reducing signs and symptoms, inhibiting structural damage progression, and improving physical function in patients with active PsA, either with or without MTX.
  • Ankylosing Spondylitis (AS): Approved for reducing signs and symptoms in patients with active AS.
  • Plaque Psoriasis (PsO): Used to treat chronic moderate to severe plaque psoriasis in patients 4 years and older who are candidates for systemic therapy or phototherapy.

Off-label Uses

Enbrel is also used off-label for a variety of conditions, including:

    • Acute Graft-Versus-Host Disease (combined with methylprednisolone)
    • Atopic Dermatitis
    • Behcet Disease
    • Hidradenitis Suppurativa
    • Kawasaki Disease
    • Keloid
    • Lichen Planus
    • Necrobiosis Lipoidica Diabeticorum
    • Pemphigus Vulgaris
    • Pityriasis Rubra Pilaris
    • Pustular Psoriasis
    • Pyoderma Gangrenosum
    • Sarcoidosis
    • Scleroderma/Systemic Sclerosis
    • Still Disease
    • Sweet’s Syndrome
    • Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome (SAPHO syndrome)
    • Toxic Epidermal Necrolysis
    • Vasculitis

Dosing and Administration

When selecting a treatment, the available dosage strengths and forms are essential considerations for ensuring proper administration and patient convenience. Below is a comparison of the dosage strengths and forms for Humira vs. Enbrel.

Humira Doses

  • Single-dose prefilled pen (HUMIRA Pen):
    • 80 mg/0.8 mL
    • 40 mg/0.8 mL
    • 40 mg/0.4 mL
  • Single-dose prefilled syringe:
    • 80 mg/0.8 mL
    • 40 mg/0.8 mL
    • 40 mg/0.4 mL
    • 20 mg/0.4 mL
    • 20 mg/0.2 mL
    • 10 mg/0.2 mL
    • 10 mg/0.1 mL
  • Single-dose vial (for institutional use only):
    • 40 mg/0.8 mL

Enbrel Doses

  • Single-dose prefilled syringe:
    • 25 mg/0.5 mL
    • 50 mg/mL
  • Single-dose prefilled SureClick® Autoinjector:
    • 50 mg/mL
  • Single-dose vial:
    • 25 mg/0.5 mL
  • Multiple-dose vial (lyophilized powder for reconstitution):
    • 25 mg
  • Enbrel Mini single-dose prefilled cartridge for use with the AutoTouch® reusable autoinjector:
    • 50 mg/mL

Here’s a detailed comparison of their respective dosages and administration guidelines:

Aspect Humira Enbrel
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis 40 mg every other week 50 mg once weekly
Juvenile Idiopathic Arthritis 10 mg every other week (10 to <15 kg)

20 mg every other week (15 to <30 kg)

40 mg every other week ( ? 30 kg)

 0.8 mg/kg weekly, maximum 50 mg per week
Hidradenitis Suppurativa For adults: 160 mg on Day 1, 80 mg on Day 15, and 80 mg every other week or 40 mg every week starting on Day 29

For adolescents (30 to <60 kg): 80 mg on Day 1, 40 mg every other week starting on Day 8

For adolescents ( ? 60 kg): 160 mg on Day 1, 80 mg on Day 15, and 80 mg every other week or 40 mg every week starting on Day 29

 Not indicated for HS
Crohn’s Disease For adults: 160 mg on Day 1, 80 mg on Day 15, and 40 mg every other week starting on Day 29

For children (17 to <40 kg): 80 mg on Day 1, 40 mg on Day 15, and 20 mg every other week starting on Day 29

For children ( ? 40 kg): 160 mg on Day 1, 80 mg on Day 15, and 40 mg every other week starting on Day 29

 Not indicated for CD
Ulcerative Colitis For adults: 160 mg on Day 1, 80 mg on Day 15, and 40 mg every other week starting on Day 29

For children (20 to <40 kg): 80 mg on Day 1, 40 mg on Day 8 and Day 15, and 40 mg every other week or 20 mg every week starting on Day 29

For children ( ? 40 kg): 160 mg on Day 1, 80 mg on Day 8 and Day 15, and 80 mg every other week or 40 mg every week starting on Day 29

 Not indicated for UC
Plaque Psoriasis 80 mg starting dose, then 40 mg every other week starting one week after the initial dose 50 mg twice weekly for 3 months, then 50 mg once weekly
Adult Uveitis 80 mg starting dose, then 40 mg every other week starting one week after the initial dose Not indicated for Uveitis

Availability of Biosimilars

A biosimilar is a type of biological product that is highly similar to an already FDA-approved biological product, known as the reference product. Biosimilars have no clinically meaningful differences in terms of safety, purity, and potency compared to the reference product. They are designed to have the same mechanism of action, route of administration, dosage form, and strength as the original biological product.

Biosimilars for Humira

Biosimilar Active Ingredient Approval Date Interchangeability with Humira Citrate-Free Latex-Free
Amjevita adalimumab-atto September 2016 No Yes Yes
Cyltezo adalimumab-adbm August 2017 Yes Yes No
Hadlima adalimumab-bwwd July 2019 No High-concentration doses are citrate-free Yes
Hulio adalimumab-fkjp July 2020 No Yes Yes
Hyrimoz adalimumab-adaz October 2018 No High-concentration doses are citrate-free Yes
Idacio adalimumab-aacf December 2022 No Yes Yes
Yuflyma adalimumab-aaty May 2023 No Yes Yes
Yusimry adalimumab-aqvh December 2021 No Yes Yes
Abrilada adalimumab-afzb November 2019 Yes Yes Yes
Simlandi adalimumab-ryvk February 2024 Yes Yes Yes

Source: CardinalHealth and GoodRx Health

Biosimilars for Enbrel

Currently, there are two FDA-approved biosimilars for Enbrel in the US–Erelzi and Eticovo. Erelzi was approved in August 2016, while Eticovo received approval in April 2019. However, both biosimilars will not be available until 2029 due to patent protections.

Although the original patent on Enbrel was set to expire in 2012, Amgen, the manufacturer of Enbrel, secured a second patent extending exclusivity until 2029. In May 2021, the US Supreme Court denied a petition by Sandoz to review the decision concerning its biosimilar Erelzi. Similarly, Samsung Bioepis, the manufacturer of Eticovo, attempted to invalidate the second patent but was unsuccessful. On November 3, 2021, the District Court of New Jersey ruled in favor of Amgen, Immunex, and Roche in the patent infringement lawsuit regarding Enbrel.

As a result, biosimilars for Enbrel won’t be available in the US until 2029.

Cost of Humira vs Enbrel

The list price for a 4-week supply of Humira is $6,922.62. In comparison, Enbrel’s list price is $1,850.46 per weekly 50 mg dose, resulting in a monthly cost of $7,401.84. For patients with moderate to severe plaque psoriasis, the recommended dose of Enbrel is 50 mg twice weekly for the first 3 months, pushing the monthly cost to $14,803.68.

Biosimilars aim to provide more cost-effective alternatives to their reference biologic products, potentially lowering expenses for patients and healthcare systems. However, these savings are relative, as biosimilars can still be expensive, often costing over $1,000. Another challenge is that Enbrel does not have a biosimilar available in the US yet, with availability not expected until 2029.

Order Humira or Enbrel from Pharma Giant Today!

For those prescribed Humira Pen or Enbrel’s SureClick pen injection, purchasing from Pharma Giant can lead to significant savings. Humira Pens at Pharma Giant start at $1,249, while Enbrel SureClick starts at $1,900. Additional discounts are available for larger quantity orders. Plus, Pharma Giant ensures expedited delivery, typically within 3-5 business days.

Takeaway

Enbrel and Humira are effective TNF inhibitors used to treat autoimmune conditions such as rheumatoid arthritis and plaque psoriasis. While Humira is slightly less expensive and has more biosimilar options, Enbrel remains a valuable treatment despite its higher cost and lack of biosimilars.

Patients should consider factors such as cost, dosing schedules, and insurance coverage when choosing between these medications. Consulting with a healthcare provider can help determine the best option based on individual needs and circumstances.

Frequently Asked Questions

Enbrel and Humira are not typically associated with significant weight gain. However, weight changes can occur as a side effect of treatment. Instances of congestive heart failure (CHF) have been observed in patients using Humira and Enbrel. CHF can cause weight gain, frequently as a result of fluid retention. If you notice swelling (edema) in your legs, ankles, or feet, experience rapid weight gain, have shortness of breath, or observe swelling in your abdomen, it’s crucial to contact your doctor promptly. These symptoms could indicate the onset or worsening of heart failure.

During the clinical trials for Humira, participants did not report hair loss (alopecia) as a side effect. However, after the FDA approved the drug, some individuals reported experiencing hair loss following its use.

The effectiveness of Humira versus Enbrel varies from person to person. Both medications are TNF inhibitors used to treat autoimmune conditions, and their efficacy depends on the specific condition, patient response, and other individual factors. Clinical trials and patient experiences suggest that both are effective, but the best choice should be made in consultation with a healthcare provider based on personal medical history and response to treatment.

Both Humira and Enbrel have similar safety profiles, as they belong to the same class of medications. The safety of these drugs can vary based on individual health conditions and potential side effects. Common risks include infections, injection site reactions, and the potential for more serious effects like malignancies. Discussing individual risk factors with a healthcare provider is essential to determine which medication may be safer for you.

Yes, Humira is considered an immunosuppressant. It works by inhibiting the action of TNF-alpha, a substance in the body that causes inflammation in autoimmune diseases. By suppressing the immune response, Humira helps reduce inflammation and disease activity but also increases the risk of infections.

Both Humira and Enbrel have specific contraindications. They should not be used in patients with known hypersensitivity to the drug or any of its components. Additionally, these medications are contraindicated in patients with severe infections such as sepsis. Patients with demyelinating diseases, such as multiple sclerosis or congestive heart failure, should use these drugs with caution. Always consult a healthcare provider to understand the contraindications based on your medical history.

Several alternatives to Humira and Enbrel exist for treating autoimmune conditions. These include other biologics like Remicade (infliximab), Simponi (golimumab), Cimzia (certolizumab pegol), and newer agents like Xeljanz (tofacitinib) and Orencia (abatacept). The choice of an alternative depends on the specific condition being treated and patient-specific factors.

Humira can start working within two to four weeks, but the full therapeutic effect may take up to three months. The onset of action can vary depending on the condition being treated and individual patient response.

There are no specific foods that must be avoided while taking Enbrel. However, maintaining a healthy diet and avoiding foods that may exacerbate the underlying condition (such as inflammatory foods for those with autoimmune conditions) is generally recommended. Consult with a healthcare provider or a dietitian for personalized dietary advice.

Enbrel may start providing relief within one to two weeks after the first dose. Similar to Humira, it can take up to three months to achieve the full therapeutic effect. The response time can differ based on the specific condition and how the individual patient responds to the medication.

The rate at which individuals metabolize medication varies. In healthy adults, it typically takes around 12 weeks (3 months) for most of the adalimumab to exit the body.

Humira and Enbrel are intended for subcutaneous injection (under the skin), not intramuscular injection. Injecting it into muscle could lead to increased pain, improper absorption, and potentially less effectiveness. Always follow the administration instructions provided by your healthcare provider to ensure proper use and effectiveness.

Related Articles